Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

23.55 -0.15 (-0.63%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about UroGen Pharma Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer
From UroGen Pharma Ltd.
Via Business Wire
News headline image
Results of the First Post-Commercial Utilization Review of JELMYTO® Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Completes Enrollment of Its Phase 3 Clinical Trial for UGN-102 in Development for Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Announces New Data from the OPTIMA II Study that Show Median Durability of Response of 24.4 Months for UGN-102, an Investigational Non-Surgical Chemoablative Treatment for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper Tract Urothelial Cancer
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Present at Evercore ISI 5th Annual Virtual HealthCONx Conference
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Highlights New Real-World Safety Data Published in The British Journal of Urology International That Showed a Low Rate of Ureteral Stenosis When Antegrade Administration of JELMYTO® was Used in Patients with Upper Tract Urothelial Carcinoma
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Announces the Appointment of Dan Wildman to the UroGen Pharma Board of Directors
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Host Thought Leader Webinar on UGN-102 and Non-Muscle Invasive Bladder Cancers
From UroGen Pharma Ltd.
Via Business Wire
News headline image
FDA Authorizes an Extension of the In-Use Period for UroGen Pharma’s JELMYTO® Admixture to 96 Hours Following Reconstitution
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Announces the Appointment of Dr. Leana S. Wen to the UroGen Pharma Board of Directors
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma Announces Upcoming 2022 Conferences
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Present at Upcoming Investor Conferences
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Office Nephrostomy Tube Administration of JELMYTO®, the only Non-Surgical, Kidney-Sparing Treatment for Adults with Low Grade Upper Tract Urothelial Cancer
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association Annual Meeting
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate Developments
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Announces FDA Clearance of IND Application for the Investigational Immunotherapy UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Corporate Developments
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Participate in Panel Discussion at Cowen 42nd Annual Healthcare Conference
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Announces Data that Shows In-Office Nephrostomy Tube Administration of Jelmyto® is Efficient for Doctors and Well Tolerated by Patients
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Announces Start of Pivotal Single-Arm Phase 3 Trial for UGN-102, an Investigational Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Present at Upcoming Conferences
From UroGen Pharma Ltd.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.